Navigation Links
Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies
Date:1/3/2009

Training Physician for both Botox and Fraxel Repair, Nissan Pilest Board Certified Dermatologist in Orange County begins in-office clinical procedure studies to track the effectiveness of using Botox as a pre-treatment to enhance the improvements of fractional CO2 skin resurfacing. Specific to this study will be resistant lip lines in women over the age of 40.

Orange County, CA (PRWEB) January 1, 2009 -- To find a solution to lip lines (also referred to as "smoker's lines"), Total Dermatology Medical Director Nissan Pilest has begun a study combining the use of Botox and Fraxel CO2 laser to address this difficult to treat problem. Many women in their 40's and beyond experience lip lines to varying degrees.

"Women tend to be more expressive in their speech and thus tend to be plagued by multiple lines radiating above and below the lips," announced Dr. Pilest. "Fraxel's new carbon dioxide laser has great promise in this area. We're using Botox as part of our Fraxel CO2 laser treatments to assure a smoother healing. Currently we're in active office clinical studies for erasing those hated vertical lipstick and smoker's lines above the lips using Botox as a 'prep' for laser resurfacing."

Botox relaxes the muscles that habitually purse in speech and thus should help the new collagen formation stay smooth during the healing process. Injected correctly, Botox can also help evert the lip border, providing the appearance of a fuller lip with a more evident restoration of the youthful cupid's bow.

Dr. Pilest, a Platinum Plus Botox provider and designated national training physician for Allergan's Botox and Juvederm products, says, "Given the option of only having a single tool in my dermatology bag, t
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy
2. BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board
3. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
4. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
5. Board Certified Dermatologist and President-Elect of the Dermatologic Society of Greater New York, Dr. Lance H. Brown Takes His Comprehensive Practice to East Hampton, NY
6. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
7. SemBioSys begins phase I/II trial of insulin produced in plant seeds
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
11. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies 
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... 2015  HealthSouth Corporation (NYSE: HLS ... post-acute healthcare services, offering both facility-based and home-based ... for the second quarter ended June 30, 2015. ... strong volume growth in both segments and an ... Grinney, President and Chief Executive Officer of HealthSouth. ...
(Date:7/29/2015)... Inc., an early stage biotech startup based on perinatal ... the Musculoskeletal Transplant Foundation of Edison NJ ... round of development of the proprietary AmnioCept™ product line ... AmnioChor,s technology allows cryopreservation of the amniotic membrane of ... those tissues. Amnion is a well-established source of multipotent ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17
... ANDS ) today announced that patient dosing has ... oral TLR7 agonist prodrug, in,patients with advanced solid tumors. ... to identify pharmacologically active doses,and preliminary antitumor activity as ... II trials., The Phase I trial is a ...
... Co., Ltd. (President:,Dr. Yuzuru Matsuda) announced that Kyowa ... U.S. subsidiary, received on February 25,2008 (local time) ... and Drug,Administration (FDA) for istradefylline (KW-6002), its investigational ... the not approvable letter FDA expressed concern if ...
... at North Carolina State University have demonstrated that ... chemically different so-called Janus particles will ... field is applied to liquid surrounding the particles. ... the Feb. 8, 2008, edition of Physical Review ...
Cached Biology Technology:Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002) 2'2-faced' particles act like tiny submarines 2
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... CITY , Jan. 24, 2013 /PRNewswire-iReach/ -- Amiigo, ... has developed a new device for gesture recognition and ... that uses accelerometers and machine learning algorithms to automatically ... device knows if users are using the elliptical trainer ...
... than geologists previously thought, according to new research results. ... put very small samples of peridotite, rock derived from Earth,s ... found that the rock can and does liquify, at least ... deep as 250 kilometers down in the mantle beneath the ...
... leading experts will meet today in Brussels, Belgium, to ... research and the key findings of FLAVIOLA an ... health benefits and potential applications. Members of the FLAVIOLA ... researchers to review the outcomes of FLAVIOLA,s research and ...
Cached Biology News:Amiigo Unveils Fitness Tracker That Knows What Exercise You're Performing 2Magma in Earth's mantle forms deeper than once thought 2Magma in Earth's mantle forms deeper than once thought 3Recent breakthroughs in cocoa flavanol research discussed by European research consortium and expert panel 2